All In Biotech

Investigational drug · Phase 3

PF-06823859

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myositis.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

7

Any phase or sponsor naming "PF-06823859"

First trial start

2023

May 20, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "PF-06823859", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Myositis

Largest trials

Live from ClinicalTrials.gov: studies naming "PF-06823859" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Myositis

  • GlucocorticoidsPhase 37 trials

    Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease

  • CRT-402Phase 21 trial

    Myeloid Therapeutics · Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.